185 related articles for article (PubMed ID: 20133685)
1. Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus.
Laursen NS; Gordon N; Hermans S; Lorenz N; Jackson N; Wines B; Spillner E; Christensen JB; Jensen M; Fredslund F; Bjerre M; Sottrup-Jensen L; Fraser JD; Andersen GR
Proc Natl Acad Sci U S A; 2010 Feb; 107(8):3681-6. PubMed ID: 20133685
[TBL] [Abstract][Full Text] [Related]
2. Full functional activity of SSL7 requires binding of both complement C5 and IgA.
Lorenz N; Clow F; Radcliff FJ; Fraser JD
Immunol Cell Biol; 2013 Aug; 91(7):469-76. PubMed ID: 23797068
[TBL] [Abstract][Full Text] [Related]
3. Functional basis for complement evasion by staphylococcal superantigen-like 7.
Bestebroer J; Aerts PC; Rooijakkers SH; Pandey MK; Köhl J; van Strijp JA; de Haas CJ
Cell Microbiol; 2010 Oct; 12(10):1506-16. PubMed ID: 20545943
[TBL] [Abstract][Full Text] [Related]
4. A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the
Yatime L; Merle NS; Hansen AG; Friis NA; Østergaard JA; Bjerre M; Roumenina LT; Thiel S; Kristensen P; Andersen GR
Front Immunol; 2018; 9():2822. PubMed ID: 30555486
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of staphylococcal superantigen-like protein 7 for complement-mediated hemolysis.
Li Y; Clow F; Fraser JD; Lin F
J Mol Med (Berl); 2018 Sep; 96(9):965-974. PubMed ID: 30066197
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for evasion of IgA immunity by Staphylococcus aureus revealed in the complex of SSL7 with Fc of human IgA1.
Ramsland PA; Willoughby N; Trist HM; Farrugia W; Hogarth PM; Fraser JD; Wines BD
Proc Natl Acad Sci U S A; 2007 Sep; 104(38):15051-6. PubMed ID: 17848512
[TBL] [Abstract][Full Text] [Related]
7. Identification of Set11 from Staphylococcus aureus Mu50 strain as a ortholog of SSL7 via bioinformatic analysis and determination of its possible targets from human serum using CNBr-pull down assays.
Li Y; Chen X; Jia N; Zhang X; Zang J
Biotechnol Lett; 2017 Sep; 39(9):1413-1423. PubMed ID: 28653102
[TBL] [Abstract][Full Text] [Related]
8. The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria.
Langley R; Wines B; Willoughby N; Basu I; Proft T; Fraser JD
J Immunol; 2005 Mar; 174(5):2926-33. PubMed ID: 15728504
[TBL] [Abstract][Full Text] [Related]
9. Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex.
Laursen NS; Andersen KR; Braren I; Spillner E; Sottrup-Jensen L; Andersen GR
EMBO J; 2011 Feb; 30(3):606-16. PubMed ID: 21217642
[TBL] [Abstract][Full Text] [Related]
10. A competitive mechanism for staphylococcal toxin SSL7 inhibiting the leukocyte IgA receptor, Fc alphaRI, is revealed by SSL7 binding at the C alpha2/C alpha3 interface of IgA.
Wines BD; Willoughby N; Fraser JD; Hogarth PM
J Biol Chem; 2006 Jan; 281(3):1389-93. PubMed ID: 16293625
[TBL] [Abstract][Full Text] [Related]
11. Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.
Schatz-Jakobsen JA; Zhang Y; Johnson K; Neill A; Sheridan D; Andersen GR
J Immunol; 2016 Jul; 197(1):337-44. PubMed ID: 27194791
[TBL] [Abstract][Full Text] [Related]
12. Episodes of natural selection shaped the interactions of IgA-Fc with FcalphaRI and bacterial decoy proteins.
Abi-Rached L; Dorighi K; Norman PJ; Yawata M; Parham P
J Immunol; 2007 Jun; 178(12):7943-54. PubMed ID: 17548632
[TBL] [Abstract][Full Text] [Related]
13. An inhibitor of complement C5 provides structural insights into activation.
Reichhardt MP; Johnson S; Tang T; Morgan T; Tebeka N; Popitsch N; Deme JC; Jore MM; Lea SM
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):362-370. PubMed ID: 31871188
[TBL] [Abstract][Full Text] [Related]
14. Structure, function and control of complement C5 and its proteolytic fragments.
Laursen NS; Magnani F; Gottfredsen RH; Petersen SV; Andersen GR
Curr Mol Med; 2012 Sep; 12(8):1083-97. PubMed ID: 22812419
[TBL] [Abstract][Full Text] [Related]
15. Structure of and influence of a tick complement inhibitor on human complement component 5.
Fredslund F; Laursen NS; Roversi P; Jenner L; Oliveira CL; Pedersen JS; Nunn MA; Lea SM; Discipio R; Sottrup-Jensen L; Andersen GR
Nat Immunol; 2008 Jul; 9(7):753-60. PubMed ID: 18536718
[TBL] [Abstract][Full Text] [Related]
16. Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.
Fung M; Lu M; Fure H; Sun W; Sun C; Shi NY; Dou Y; Su J; Swanson X; Mollnes TE
Clin Exp Immunol; 2003 Aug; 133(2):160-9. PubMed ID: 12869020
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting the C5-C5a receptor axis.
Woodruff TM; Nandakumar KS; Tedesco F
Mol Immunol; 2011 Aug; 48(14):1631-42. PubMed ID: 21549429
[TBL] [Abstract][Full Text] [Related]
18. Terminal complement components play a role in the expression of C5a.
Gresham HD; Renfer L; Hammer CH; Frank MM
J Immunol; 1987 Feb; 138(3):838-41. PubMed ID: 3805718
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for therapeutic inhibition of complement C5.
Jore MM; Johnson S; Sheppard D; Barber NM; Li YI; Nunn MA; Elmlund H; Lea SM
Nat Struct Mol Biol; 2016 May; 23(5):378-86. PubMed ID: 27018802
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies.
Struijf EM; De la O Becerra KI; Ruyken M; de Haas CJC; van Oosterom F; Siere DY; van Keulen JE; Heesterbeek DAC; Dolk E; Heukers R; Bardoel BW; Gros P; Rooijakkers SHM
J Biol Chem; 2023 Aug; 299(8):104956. PubMed ID: 37356719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
